



Sicong Zhang, Xianming Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang

Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

High-grade B-cell lymphoma (HL) is a highly aggressive hematologic malignancy... (The text is severely distorted and largely illegible due to heavy noise and artifacts.)

(Table 1).

Treatment strategies for early-stage HL

Treatment strategies for early-stage HL... (The text is severely distorted and largely illegible due to heavy noise and artifacts.)

Progress in developing novel therapies for HL in 2023

HL

Study population

a a f a ff .  
S a a ff a a a  
ff f PD1 a a . A  
17 I a a C f Ma a L a  
(17-ICML), H a a .<sup>3</sup> a f  
SWOG S1826 a a a -  
a BV-AVD, a (N)-AVD PFS a  
a f a a a -  
a a HL. T a a -  
a f a a HL.  
H a a f a a  
a a (OS) f a ; f ,  
f . A a a a -  
a ff f a a AVD ( a ,  
a a a a ; APVD) a  
HL. T 2- a PFS a OS, 97% a 100%, -  
a fa a af a ff a <sup>14</sup>. A  
a a a a -PD1 a  
a a ff a a  
a HL.

F a a a HL a a , a  
ff f a a a -  
a . T C O  
G (COG) a a a fa a -  
a a a a 30 a .  
H a a f a a a  
a a f a a a  
fa a f a a a  
f a a a a . T f ,  
a a f a a a a  
f a a a  
a a a ff . T  
a 2( ) . -  
/ , a a a (COPDAC-28) -  
a 7P a a a af a

a ff a f ( )17 (a) 2.9( )10.1( )TJ0.162 T<sub>1</sub> 0 -1.474 TD(a )17( . a)-2( )3( , )  
h<sub>2</sub> 2 ( P ) 1 COPDAC-28-(a35 (1.5( 1 a 7P )Ta)-2( 4.1 ( )T0f )II0.15 TB )-117( a 3 h T)- )-39 4)9(2)39 J)-3( a(3( )  
6 a a - 3 0 ( . 1 ) 3 ( ) T J . 9 . a 5 ( ) 3 2 7 P a a V 1 1 (



